Pluri Inc.
PLURAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 2, 2025 | Industrial Alliance Securities | Matthew Venezia | $12.00(+168%) | $4.47 | TheFly |
Earnings History
Next report: Mar 3, 2027| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 10, 2026 | $-0.54 | $-0.66 | $335.0K | $655.0K |
| May 14, 2026 | $-0.55 | $-0.66 | $167.0K | $655.0K |
| Feb 12, 2026 | $-0.71 | $-0.65 | $198.0K | $638.0K |
| Nov 12, 2025 | $-0.65 | $-0.74 | $316.0K | $638.0K |
| Sep 17, 2025 | $-2.62 | $-0.65 | $398.0K | $638.0K |
| May 13, 2025 | $-0.94 | $-0.73 | $427.0K | $400.0K |
| Feb 11, 2025 | $-0.53 | — | $185.0K | — |
| Nov 12, 2024 | $-1.08 | — | $326.0K | $80.1M |
News
Pluri Inc. (PLUR) Discusses Commercialization Strategy, ZEO ScientifiX Transaction and Financial Flexibility Transcript
Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational resources. Complementary technology and development capabilities: Pluri brings extensive experience in cell-based product development, clinical experience extending through Phase III trials and scalable manufacturing methods and expertise developed through its proprietary 3D cell-expansion plat…
HAIFA, Israel and EDINBURGH, Scotland, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Ever After Foods (EAF) and Roslin Technologies today announced results from their joint cultivated meat production program. Combining Roslin Technologies' advanced cell platform with Ever After Foods' proprietary Edible Packed Bed (EPB™) technology, the companies demonstrated substantial gains in protein and biomass productivity while producing structured tissue directly within a scalable and food-grade process.
Pluri (NASDAQ: PLUR - Get Free Report) is expected to post its results after the market closes on Wednesday, September 23rd. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $0.6550 million for the quarter. Pluri (NASDAQ: PLUR - Get Free Report) last released its earnings results on Thursday, September 10th. The
HAIFA, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human Health & Longevity and (ii) FoodTech & Bio-Farming, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor, for the purchase and sale of 2,228,940 Common Shares (or Common Sha…
Plurilock Security Inc. (PLUR:CA) Discusses Corporate Update and Growth Strategy in Defense Contracting Portfolio Transcript
Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence